Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 1
2010 1
2011 1
2012 3
2013 4
2014 6
2015 3
2016 7
2017 3
2018 6
2019 4
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

39 results
Results by year
Filters applied: . Clear all
Page 1
Linifanib exerts dual anti-obesity effect by regulating adipocyte browning and formation.
Zhao S, Chu Y, Zhang Y, Zhou Y, Jiang Z, Wang Z, Mao L, Li K, Sun W, Li P, Jia S, Wang C, Xu A, Loomes K, Tang S, Wu D, Hui X, Nie T. Zhao S, et al. Among authors: Zhou Y. Life Sci. 2019 Apr 1;222:117-124. doi: 10.1016/j.lfs.2019.01.047. Epub 2019 Jan 29. Life Sci. 2019. PMID: 30708100
Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer.
Xiang Q, Zhang Y, Li J, Xue X, Wang C, Song M, Zhang C, Wang R, Li C, Wu C, Zhou Y, Yang X, Li G, Ding K, Xu Y. Xiang Q, et al. Among authors: Zhou Y. ACS Med Chem Lett. 2018 Feb 13;9(3):262-267. doi: 10.1021/acsmedchemlett.8b00003. eCollection 2018 Mar 8. ACS Med Chem Lett. 2018. PMID: 29541371 Free PMC article.
Protective effect of vitamin E against acute kidney injury.
Liu P, Feng Y, Wang Y, Zhou Y, Zhao L. Liu P, et al. Among authors: Zhou Y. Biomed Mater Eng. 2015;26 Suppl 1:S2133-44. doi: 10.3233/BME-151519. Biomed Mater Eng. 2015. PMID: 26405992 Review.
Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.
Xiang Q, Wang C, Zhang Y, Xue X, Song M, Zhang C, Li C, Wu C, Li K, Hui X, Zhou Y, Smaill JB, Patterson AV, Wu D, Ding K, Xu Y. Xiang Q, et al. Among authors: Zhou Y. Eur J Med Chem. 2018 Mar 10;147:238-252. doi: 10.1016/j.ejmech.2018.01.087. Epub 2018 Feb 6. Eur J Med Chem. 2018. PMID: 29448139
Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC).
Zhang M, Zhang Y, Song M, Xue X, Wang J, Wang C, Zhang C, Li C, Xiang Q, Zou L, Wu X, Wu C, Dong B, Xue W, Zhou Y, Chen H, Wu D, Ding K, Xu Y. Zhang M, et al. Among authors: Zhou Y. J Med Chem. 2018 Apr 12;61(7):3037-3058. doi: 10.1021/acs.jmedchem.8b00103. Epub 2018 Apr 3. J Med Chem. 2018. PMID: 29566488
39 results
Jump to page
Feedback